Liposomal delivery as a mechanism to enhance synergism between anticancer drugs

Molecular Cancer Therapeutics

Volumn 5, Issue 7, 2006, Pages 1639-1640

  Lee, Robert J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLOXURIDINE; IRINOTECAN; LIPOSOME; MACROGOL; NUCLEIC ACID; VERAPAMIL;

CHEMICAL MODIFICATION; CONTROLLED RELEASE FORMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STABILITY; ENCAPSULATION; HUMAN; HYPERTHERMIA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NOTE; PARTICLE SIZE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SOLID TUMOR; TEMPERATURE SENSITIVITY;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; HUMANS; LIPOSOMES; VEHICLES;

EID: 33748321118     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-C02     Document Type: Note

References (11)

1. Mauer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 2001;6:923-47.
2. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.
3. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36.
4. Abraham SA, Edwards K, Karlsson G, et al. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 2002;1565: 41-54.
5. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989;337:387-8.
6. Straubinger RM, Duzgunes N, Papahadjopoulus D. pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett 1985;179:148-54.
7. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53: 285-305.
8. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2:369-81.
9. Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5:1854-63.
10. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 1997;280: 1406-14.
11. Wang J, Goh B, Lu W, et al. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 2005;28:822-8.